Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Gautherot, Emmanuel ^a   Kraeber Bodéré, Françoise ^b   Daniel, Laurent ^c   Fiche, Maryse ^d   Rouvier, Éric ^a   Saï Maurel, Catherine ^b   Thedrez, Philippe ^b   Chatal, Jean François ^b   Barbet, Jacques ^a  

^a Immunotech   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CHU de Nantes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DIPENTETIC ACID INDIUM TYROSYLLYSINE BIVALENT HAPTEN I 131; HAPTEN; IODINE 131; KI 67 ANTIGEN; PENTETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0032723745     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Le Doussal, J. M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res., 50: 3445-3452, 1990.
2. Gautherot, E., Le Doussal, J. M., Bouhou, J., Manetti, C., Martin, M., Rouvier, E., and Barbet, J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J. Nucl. Med., 39: 1937-1943, 1998.
3. Hosono, M., Hosono, M. N., Kraeber-Bodéré, F., Devys, A., Thedrez, P., Fiche, M., Gautherot, E., Barbet. J., and Chatal, J. F. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J. Nucl. Med., 39: 1608-1613, 1998.
4. 131I-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J. Nucl. Med., 37: 1853-1859, 1996.
5. Gautherot, E., Bouhou, J., Le Doussal, J. M., Manetti, C., Martin, M., Rouvier, E., and Barbet, J. Therapy for colon carcinoma xenografts with bispecific antibody-targeted iodine-131-labeled bivalent hapten. Cancer (Phila.), 80 (Suppl.): 2618-2623, 1997.
6. Kraeber-Bodéré, F., Faivre-Chauvet, A., Saï-Maurel, C., Gautherot, E., Fiche, M., Campion, L., Le Boterff, J., Barbet, J., Chatal, J. F., and Thédrez, P. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J. Nucl. Med.. 40: 198-204, 1999.
7. Blumenthal, R. D., Sharkey, R. M., Natale, A. M., Kashi, R., Wong, G., and Goldenberg, D. M. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res., 54: 142-151, 1994.
8. Buchegger, F., Rojas, A., Bischof-Delaloye, A., Vogel, C. A., Mirimanoff, R. O., Coucke, P., Sun, L. Q., Raimondi, S., Denekamp, J., Pélegrin, A., Delaloye, B., and Mach, J. P. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res., 55: 83-89, 1995.
9. Pedley, R. B., Boden, J. A., Boden, R., Boxer, G. M., Flynn, A. A., Keep, P. A., and Begent, R. H. J. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res., 56: 3293-3300, 1996.
10. Brambilla, E., Moro, D., Gazzeri, S., Brichon, P. Y., Naguy-Mignotte, H., Morel, F., Jacrot, M., and Brambilla, C. Cytotoxic chemotherapy induces cell differentiation in small cell lung carcinoma. J. Clin. Oncol., 9: 50-61, 1991.
11. Iwasaka, T., Fukuda, K., Hara, K., Yokoyama, M., Nakao, Y., Uchiyama, M., and Sugimori, H. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix. Gynecol. Oncol., 70: 236-240, 1998.
12. Esteban, J. M., Schlom, J., Mornex, F., and Colcher, D. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur. J. Cancer Clin. Oncol., 23: 643-655, 1987.
13. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H. Cell cycle analysis of cell proliferation analysis-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 33: 1710-1715, 1984.
14. Behr, T. M., Wulst, E., Radetzky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-Frank, M., Schmidberger, H., Raue, F., and Becker. W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57: 5309-5319, 1997.
15. Peterson, J. A., Blank, E. W., and Ceriani, R. L. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas. Cancer Res., 57: 1103-1108, 1997.
16. 177Lutetium-labeled immunoconjugate. Cancer Res., 51: 2889-2896, 1991.
17. Robbins, S. L., Cotran, R. S., and Kumar, V. Environmental pathology. In: Pathologic Basis of Disease, pp. 466-467. Philadelphia: W. B. Saunders Co., 1984.
18. 2 and pretargeted bivalent hapten and evaluation of repeated infections. Clin. Cancer Res., 5 (Suppl.): 3183s-3189s, 1999.